Navigation Links
BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
Date:4/22/2008

SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its underwriters have exercised their over-allotment option to purchase additional shares of common stock in connection with BioMed's previously announced follow-on offering that priced on April 17, 2008. In total, the company sold 6,129,000 shares of common stock, raising gross offering proceeds of approximately $156.3 million.

The underwriters for the offering are Raymond James & Associates, Inc., Morgan Stanley & Co. Incorporated, Wachovia Capital Markets, LLC, KeyBanc Capital Markets Inc., Robert W. Baird & Co. Incorporated, Credit Suisse Securities (USA) LLC, RBC Capital Markets Corporation and Stifel, Nicolaus & Company, Incorporated.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed's common stock, nor shall there be any sale of such common stock in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering of BioMed's common stock is being made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained by contacting Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716, or by calling toll-free at 1 (800) 248-8863.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 68 properties, representing 104 buildings with approximately 8.5 million rentable square feet, as well as approximately 1.9 million square feet of development in progress. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock
2. BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
3. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
4. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
5. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
6. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
7. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
8. LifeNet Health(R) Unveils New Biomedical Spine Implant
9. MIT researcher addresses biomedical engineering challenges
10. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
11. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , ... February 08, 2016 , ... ... testing services, announced today the launch of its revamped and improved website. In ... language service solutions, the redesigned website will better communicate how the company designs ...
(Date:2/9/2016)... ... ... The American Academy of Thermology (AAT) has announced that for the ... Qualification Course for Technicians via a two part webinar on July 30 and August ... of hardware, software, and camera setup/operations, aligns with the in-person member qualification course that ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... 9, 2016 Three-Year Initiative Supports Next ... Take Part in Life-Changing Camp Experiences ... to positively affect the lives of children born with rare diseases, ... SHPG ) is announcing a new initiative designed to positively ... as the future of rare disease care. --> To ...
Breaking Biology Technology:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
Breaking Biology News(10 mins):